Shots:

• PureTech to receive $26M as an upfront including research funding & preclinical milestone- $200M as development and commercial milestones and royalties on sales. Boehringer to develop immune-oncology candidates after it enters to development stage by utilizing PureTech’s lymphatic targeting technology
• The focus of the collaboration is to develop immuno-oncology candidates for gastrointestinal (GI) cancers administered directly to the gut lymphatics to potentially tune systemic and local immunity
• PureTech’s lymphatic targeting technology is designed to enable the transport of drug directly into the lymphatic system when administered orally targeting cancer- inflammatory and autoimmune diseases

Ref: Puretech | Image: Pinterest